The Efficacy and Safety of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study
- PMID: 38445000
- PMCID: PMC10910368
The Efficacy and Safety of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study
Figures
References
-
- Hanzel J, Hulshoff MS, Grootjans J, D’Haens G. Emerging therapies for ulcerative colitis. Expert Rev Clin Immunol. 2022;18(5):513–524. - PubMed
-
- Allegretti JR, Peyrin-Biroulet L, Feagan BG The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 Quasar induction study. Abstract 913b. 2023. Presented at: DDW 2023; May 6-9. Chicago, Illinois. - PMC - PubMed
-
- First phase 3 TREMFYA® (guselkumab) data in inflammatory bowel disease show positive induction results among patients with moderately to severely active ulcerative colitis [press release]. Spring House, Pennsylvania. Johnson & Johnson. May 9, 2023.
LinkOut - more resources
Full Text Sources